Research programme: RNA therapeutics- Arcturus Therapeutics/Synthetic Genomics

Drug Profile

Research programme: RNA therapeutics- Arcturus Therapeutics/Synthetic Genomics

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arcturus Therapeutics; Synthetic Genomics
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 31 Oct 2017 Arcturus Therapeutics and Synthetic Genomics agree to co-develop RNA therapeutics worldwide
  • 31 Oct 2017 Arcturus Therapeutics has patent protection for LUNAR lipid-mediated delivery and UNA technology including UNA oligomers in USA, Europe, Japan, China and other countries
  • 31 Oct 2017 Arcturus Therapeutics has patents pending for LUNAR lipid-mediated delivery and UNA technology including UNA oligomers in USA, Europe, Japan, China and other countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top